Mind Medicine Subordinate Voting I
Clinical-stage biopharma Mind Medicine develops psychedelic‑derived treatments for brain disorders, with MM120 in Phase 3 for GAD/ADHD and MM402 in Phase I targeting core autism symptoms. HQ New York, focused on innovation in mental health.
Headquarters: Canada (CAN)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Alternative Medicine
- Employees: 74
- HQ: New York
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.